Raymond James Financial Services Advisors Inc. Sells 3,380 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Raymond James Financial Services Advisors Inc. lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 45.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,024 shares of the medical equipment provider’s stock after selling 3,380 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Lantheus were worth $249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tucker Asset Management LLC boosted its holdings in shares of Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 282 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 225 shares during the last quarter. Covestor Ltd grew its holdings in Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 203 shares during the last quarter. Parkside Financial Bank & Trust increased its position in shares of Lantheus by 36.6% during the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 156 shares in the last quarter. Finally, NBC Securities Inc. purchased a new stake in shares of Lantheus during the 3rd quarter valued at $46,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research report on Friday, February 23rd. Truist Financial reissued a “buy” rating and set a $82.00 target price (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. Finally, B. Riley raised their price target on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $104.71.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders have sold 94,545 shares of company stock valued at $6,169,936 in the last 90 days. 2.10% of the stock is currently owned by company insiders.

Lantheus Stock Up 2.1 %

NASDAQ:LNTH opened at $64.41 on Wednesday. The firm has a market capitalization of $4.42 billion, a P/E ratio of 13.92 and a beta of 0.54. The company’s fifty day moving average price is $60.94 and its 200-day moving average price is $62.78. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $100.85. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.72 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.